

UNITED STATES CONTINUING UTILITY PATENT APPLICATION
under 37 C.F.R. § 1.53(b)

Atty. Docket No. 01107.00042

68/22/00
Page 1
P1

Assistant Commissioner of Patents
Box Patent Applications
Washington, D.C. 20231

1C062 U.S. PRO
09/642660
68/22/00

Enclosed herewith is a continuing patent application and the following papers:

First Named Inventor (or application identifier): Jonathan Schneck

Title of Invention: Molecular Complexes which Modify Immune Responses

- Continuation
- Divisional
- Continuation-in-Part

of prior application No. 09/063,276, filed April 21, 1998

Specification 63 pages (including specification, claims, abstract) / 50 claims (12 independent)

1.
2.
Declaration/Power of Attorney:
 - Copy from Prior Application (for continuation or divisional application)
 - Newly Executed Declaration (for CIP application)
 - Deferred under 37 C.F.R. § 1.53(f)
3.
21 Distinct sheets of Formal Informal Drawings
4.
Preliminary Amendment
5.
Information Disclosure Statement
 - Form 1449
 - A copy of each cited prior art reference
6.
Assignment
 - Assignment with Cover Sheet attached
 - Assignment filed in prior application. Application assigned to: Johns Hopkins University

UNITED STATES CONTINUING UTILITY PATENT APPLICATION
under 37 C.F.R. § 1.53(b)

Atty. Docket No. 01107.00042

Page 2

7. Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)
US	60/014,367	28 March 1996

- 7a. Priority is hereby claimed under 35 U.S.C. § 120 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)
US	08/828,172	28 March 1997

8. Priority Document(s)

- was filed in prior application
- is attached
- will be submitted prior to or concurrently with the payment of any issue fee for the instant application

9. Small Entity Statement

- Small Entity Statement was filed in prior application, Small Entity Status is still proper and desired
- is attached
- is no longer claimed

10. Microfiche Computer Program (Appendix)

11. Nucleotide and/or Amino Acid Sequence Submission

- Computer Readable Copy
- Paper Copy (identical to computer copy)
- Statement verifying identity of above copies

UNITED STATES CONTINUING UTILITY PATENT APPLICATION
under 37 C.F.R. § 1.53(b)

Atty. Docket No. 01107.00042

Page 3

12. Calculation of Fees:

FEES FOR	EXCESS CLAIMS	Fee	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))			\$690.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	30	18.00	\$540.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	9	78.00	\$702.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	0	260.00	\$0.00
Subtotal - Filing Fee Due			\$1,932.00
		MULTIPLY BY	
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0.50		\$966.00
TOTAL FILING FEE DUE			\$966.00
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	\$0.00
GRAND TOTAL DUE			\$966.00

13. PAYMENT is:


- included in the amount of the GRAND TOTAL by our enclosed check. A general authorization under 37 C.F.R. § 1.25(b), second sentence, is hereby given to credit or debit our Deposit Account No. 19-0733 for the instant filing and for any other fees during the pendency of this application under 37 C.F.R. §§ 1.16, 1.17 and 1.18
- not included, but deferred under 37 C.F.R. § 1.53(f).

14. All correspondence for the attached application should be directed to:

Banner & Witcoff, Ltd.
1001 G Street, N.W.
Washington, D.C. 20001-4597
Telephone: (202) 508-9100
Facsimile: (202) 508-9299

15. Other: _____

Date: August 22, 2000

By: 
Sarah A. Kagan
Reg. No. 32,141

SAK/ama